Patents by Inventor Rajesh R. Shinde
Rajesh R. Shinde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220395498Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.Type: ApplicationFiled: July 29, 2022Publication date: December 15, 2022Inventors: Leila Alland, Christopher Sears, Rajesh R. Shinde, Beata Sweryda-Krawiec, Tsun P. Au Yeung, Mark T. Bilodeau, Sudhakar Kadiyala, Eugene Zhorov, Richard Wooster
-
Patent number: 11510910Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.Type: GrantFiled: December 12, 2019Date of Patent: November 29, 2022Assignee: TVA (ABC), LLCInventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
-
Patent number: 11458206Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: February 18, 2020Date of Patent: October 4, 2022Assignee: TVA (ABC), LLCInventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20220288229Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: May 23, 2022Publication date: September 15, 2022Inventors: Mark T. Bilodeau, Sudhakar Kadiyala, Rajesh R. Shinde, Brian H. White, Richard Wooster, Benoît Moreau
-
Publication number: 20220096640Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: December 9, 2021Publication date: March 31, 2022Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Publication number: 20220096646Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: September 30, 2021Publication date: March 31, 2022Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
-
Publication number: 20220054647Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: November 4, 2021Publication date: February 24, 2022Inventors: Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
-
Patent number: 11241500Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: December 14, 2017Date of Patent: February 8, 2022Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Patent number: 11213590Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: October 27, 2017Date of Patent: January 4, 2022Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
-
Patent number: 11160871Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: GrantFiled: October 28, 2016Date of Patent: November 2, 2021Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Richard Wooster, Kerry Whalen, Patrick Rosaire Bazinet, Mark T. Bilodeau, Sudhakar Kadiyala, Samantha Perino, Beata Sweryda-Krawiec, Rajesh R. Shinde
-
Publication number: 20210169871Abstract: The present invention provides improved formulation with reduced tert-butanol levels and/or manufacturing process for drug compounds that form a solvate with tert-butanol. For example, the drug compound may be SDC-TRAP-0063.Type: ApplicationFiled: April 3, 2019Publication date: June 10, 2021Applicant: Tarveda Therapeutics, Inc.Inventors: Mark T. BILODEAU, Eugene ZHOROV, Rajesh R. SHINDE, Christopher SEARS, Samantha BRADY, Beata SWERYDA-KRAWIEC
-
Publication number: 20200281934Abstract: Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, have been designed. Methods of administering the conjugates to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: October 26, 2018Publication date: September 10, 2020Inventors: Rajesh R. Shinde, Rossitza G. Alargova, Patrick Lim Soo, Beata Sweryda-Krawiec, Leila Alland, Christopher Sears
-
Publication number: 20200237746Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.Type: ApplicationFiled: June 19, 2018Publication date: July 30, 2020Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
-
Publication number: 20200230126Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.Type: ApplicationFiled: June 19, 2018Publication date: July 23, 2020Inventors: Leila Alland, Christopher Sears, Rajesh R. Shinde, Beata Sweryda-Krawiec, Tsun P. Au Yeung, Mark T. Bilodeau, Sudhakar Kadiyala, Eugene Zhorov, Richard Wooster
-
Publication number: 20200206356Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: February 18, 2020Publication date: July 2, 2020Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20200121808Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: ApplicationFiled: December 20, 2019Publication date: April 23, 2020Inventors: Mark T. Bilodeau, Sudhakar Kadiyala, Rajesh R. Shinde, Brian H. White, Richard Wooster, Benoît Moreau
-
Patent number: 10624967Abstract: Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.Type: GrantFiled: July 18, 2017Date of Patent: April 21, 2020Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rossitza G. Alargova, Mark T. Bilodeau, Craig A. Dunbar, Sudhakar Kadiyala, Rajesh R. Shinde, Patrick Lim Soo, Beata Sweryda-Krawiec, Brian H. White, Patrick Rosaire Bazinet, Richard Wooster
-
Publication number: 20200113877Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.Type: ApplicationFiled: December 12, 2019Publication date: April 16, 2020Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala
-
Publication number: 20200085960Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.Type: ApplicationFiled: December 14, 2017Publication date: March 19, 2020Inventors: Benoît Moreau, Brian H. White, Mark T. Bilodeau, Mary Simcox, Kerry Whalen, Leila Alland, Richard Wooster, Rajesh R. Shinde
-
Patent number: 10548881Abstract: Conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to an HSP90 targeting moiety via a linker have been designed. Nanoparticles and microparticles comprising such conjugates can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or other diseases.Type: GrantFiled: February 23, 2017Date of Patent: February 4, 2020Assignee: TARVEDA THERAPEUTICS, INC.Inventors: Rajesh R. Shinde, Mark T. Bilodeau, Richard Wooster, Sudhakar Kadiyala